<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881112463470</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881112463470</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Differential effects of antipsychotic agents on obsessive–compulsive symptoms in schizophrenia: a longitudinal study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Schirmbeck</surname><given-names>Frederike</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112463470">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rausch</surname><given-names>Franziska</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112463470">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Englisch</surname><given-names>Susanne</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112463470">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Eifler</surname><given-names>Sarah</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112463470">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Esslinger</surname><given-names>Christine</given-names></name>
<xref ref-type="aff" rid="aff2-0269881112463470">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Meyer-Lindenberg</surname><given-names>Andreas</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112463470">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zink</surname><given-names>Mathias</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112463470">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881112463470"><label>1</label>Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany</aff>
<aff id="aff2-0269881112463470"><label>2</label>Department of Neurology, Otto-von-Guericke-University, Magdeburg, Germany</aff>
<author-notes>
<corresp id="corresp1-0269881112463470">Frederike Schirmbeck, Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim/Heidelberg University, PO Box 12 21 20, D-68072 Mannheim, Germany. Email: <email>frederike.schirmbeck@zi-mannheim.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>27</volume>
<issue>4</issue>
<fpage>349</fpage>
<lpage>357</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Indirect evidence supports the assumption that antiserotonergic second-generation antipsychotics (SGA) induce and aggravate obsessive–compulsive symptoms (OCS) in schizophrenia. However, multimodal studies assessing the long-term interaction of pharmacotherapy and psychopathology are missing. Over 12 months, we followed-up 75 schizophrenia patients who were classified into two groups according to antipsychotic treatment: clozapine or olanzapine (group I) versus aripiprazole or amisulpride (group II). We applied the Yale Brown Obsessive Compulsive Scale (YBOCS) and investigated between-group changes over time as the primary endpoint. Group I showed markedly higher YBOCS scores at both time points. Repeated measure analyses of variance (ANOVAs) revealed significant interaction effects of group and time (per protocol sample (PP): <italic>p</italic>=0.006). This was due to persistently high OCS severity within group I, and decreasing YBOCS scores within group II. OCS severity correlated significantly with the negative and general psychopathology subscales of the Positive and Negative Syndrome Scale (PANSS), as well as with depressive symptoms. The progressive differences in OCS severity between our groups support the assumption of differential pharmacodynamic effects on comorbid OCS in schizophrenia. Further studies should address the pathogenetic mechanism, define patients at risk and facilitate early detection as well as therapeutic interventions.</p>
</abstract>
<kwd-group>
<kwd>Antipsychotic agents</kwd>
<kwd>clozapine</kwd>
<kwd>comorbidity</kwd>
<kwd>compulsion</kwd>
<kwd>obsession</kwd>
<kwd>OCS</kwd>
<kwd>schizophrenia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881112463470" sec-type="intro">
<title>Introduction</title>
<p>The co-occurrence of obsessive–compulsive symptoms (OCS) and schizophrenia has interested scientists since Carl Friedrich Otto Westphal in the 19th century (<xref ref-type="bibr" rid="bibr52-0269881112463470">Westphal, 1878</xref>). Recent epidemiological investigations estimate that about 12% of schizophrenia patients also fulfil the criteria for obsessive–compulsive disorder, while almost every fourth patient reports comorbid OCS (<xref ref-type="bibr" rid="bibr1-0269881112463470">Achim et al., 2011</xref>; <xref ref-type="bibr" rid="bibr6-0269881112463470">Buckley et al., 2009</xref>; <xref ref-type="bibr" rid="bibr32-0269881112463470">Lysaker and Whitney, 2009</xref>; <xref ref-type="bibr" rid="bibr34-0269881112463470">Mukhopadhaya et al., 2009</xref>; <xref ref-type="bibr" rid="bibr38-0269881112463470">Poyurovsky et al., 2004</xref>, <xref ref-type="bibr" rid="bibr39-0269881112463470">2012</xref>). Comorbid OCS in schizophrenia is linked with poorer social and vocational function (<xref ref-type="bibr" rid="bibr15-0269881112463470">de Haan et al., 2011</xref>; <xref ref-type="bibr" rid="bibr19-0269881112463470">Fenton and McGlashan, 1986</xref>) and heightened levels of anxiety and depression (<xref ref-type="bibr" rid="bibr32-0269881112463470">Lysaker and Whitney, 2009</xref>). These additional impairments lead to a poor overall prognosis.</p>
<p>Several causal explanations for this high percentage of co-occurrence have been proposed. Within the range of possible pathomechanisms the hypothesis arose that second-generation antipsychotics (SGAs) with pronounced antiserotonergic pharmacodynamic properties, in particular clozapine (CLZ), might induce second-onset OCS as a side effect (<xref ref-type="bibr" rid="bibr29-0269881112463470">Kwon et al., 2009</xref>; <xref ref-type="bibr" rid="bibr31-0269881112463470">Lykouras et al., 2003</xref>). First hints towards this assumed causal interaction were provided by case reports (<xref ref-type="bibr" rid="bibr3-0269881112463470">Baker et al., 1992</xref>; <xref ref-type="bibr" rid="bibr56-0269881112463470">Zink et al., 2006</xref>, <xref ref-type="bibr" rid="bibr55-0269881112463470">2007</xref>), cases series (<xref ref-type="bibr" rid="bibr17-0269881112463470">Englisch et al., 2009</xref>) and systematic evaluations (<xref ref-type="bibr" rid="bibr13-0269881112463470">de Haan et al., 1999</xref>, <xref ref-type="bibr" rid="bibr14-0269881112463470">2004</xref>; <xref ref-type="bibr" rid="bibr31-0269881112463470">Lykouras et al., 2003</xref>) which reported de-novo onset of OCS after first manifestation of psychosis and initiation of SGA treatment. The high OCS prevalence in CLZ-treated samples and significant correlations of OCS severity with CLZ dosage, serum levels or duration of treatment further indicated an induction of OCS by SGAs within a significant subgroup of comorbid patients (<xref ref-type="bibr" rid="bibr30-0269881112463470">Lin et al., 2006</xref>; <xref ref-type="bibr" rid="bibr34-0269881112463470">Mukhopadhaya et al., 2009</xref>; <xref ref-type="bibr" rid="bibr40-0269881112463470">Reznik et al., 2004</xref>; <xref ref-type="bibr" rid="bibr47-0269881112463470">Schirmbeck and Zink, 2012</xref>; <xref ref-type="bibr" rid="bibr45-0269881112463470">Schirmbeck et al., 2011</xref>). Noteworthy, while similar associations have been reported for the closely related SGA olanzapine (OLZ) (<xref ref-type="bibr" rid="bibr10-0269881112463470">de Haan et al., 2002</xref>), this has not been the case for predominantly dopaminergic SGAs such as amisulpride (AMS) (<xref ref-type="bibr" rid="bibr44-0269881112463470">Scatton et al., 1997</xref>) or the partial dopaminergic/serotonergic agonist aripiprazole (APZ) (<xref ref-type="bibr" rid="bibr49-0269881112463470">Sparshatt et al., 2010</xref>). These two substances rather seem to be beneficial or at least neutral regarding OCS (<xref ref-type="bibr" rid="bibr8-0269881112463470">Connor et al., 2005</xref>; <xref ref-type="bibr" rid="bibr26-0269881112463470">Kim et al., 2008</xref>; <xref ref-type="bibr" rid="bibr35-0269881112463470">Muscatello et al., 2011</xref>; <xref ref-type="bibr" rid="bibr54-0269881112463470">Yang et al., 2008</xref>; <xref ref-type="bibr" rid="bibr56-0269881112463470">Zink et al., 2006</xref>). Preliminary evidence showed marked improvement of OCS under combination treatment with CLZ and APZ, in cases with subsequent CLZ dose reductions (<xref ref-type="bibr" rid="bibr17-0269881112463470">Englisch et al., 2009</xref>; <xref ref-type="bibr" rid="bibr41-0269881112463470">Rocha and Hara, 2006</xref>; <xref ref-type="bibr" rid="bibr51-0269881112463470">Villari et al., 2011</xref>; <xref ref-type="bibr" rid="bibr56-0269881112463470">Zink et al., 2006</xref>) as well as under constant CLZ dose (<xref ref-type="bibr" rid="bibr7-0269881112463470">Chang et al., 2008</xref>). Epidemiological and pharmacological data therefore propose differential effects of SGAs on OCS (<xref ref-type="bibr" rid="bibr47-0269881112463470">Schirmbeck and Zink, 2012</xref>), but research assessing the longitudinal course of OCS in schizophrenia is very limited (<xref ref-type="bibr" rid="bibr15-0269881112463470">de Haan et al., 2011</xref>). To the best of our knowledge only one study investigated the longitudinal interaction of antipsychotic treatment and comorbid OCS in schizophrenia by assessing OCS during treatment with olanzapine and risperidone over a 6-week time period (<xref ref-type="bibr" rid="bibr10-0269881112463470">de Haan et al., 2002</xref>). Therefore, prospective research focusing on pharmacodynamic aspects and their effects on comorbid OCS in schizophrenia is needed.</p>
<p>We are well aware that in order to prove causal interactions a randomized controlled trial would be necessary (<xref ref-type="bibr" rid="bibr5-0269881112463470">Bradford Hill, 2011</xref>). Since ethical and legal conditions preclude this obvious design of a randomized trial involving CLZ, longitudinal observations seem indicated to substantiate hypothesized pro-obsessive effects of mainly serotonergic SGAs (<xref ref-type="bibr" rid="bibr13-0269881112463470">de Haan et al., 1999</xref>; <xref ref-type="bibr" rid="bibr47-0269881112463470">Schirmbeck and Zink, 2012</xref>).</p>
<p>We therefore conducted this longitudinal study as a part of a comprehensive multimodal project. At baseline, patients were classified into two groups according to the medication they were receiving in monotherapy as part of their treatment as usual. In a previously published first cross-sectional evaluation of a subsample of 70 individuals we compared onset, prevalence, and severity of OCS in relation to SGA treatment: schizophrenia patients treated with CLZ and OLZ (group I) suffered more frequently and more severely from OCS than patients under AMS or APZ treatment (group II) and significant correlations between OCS severity and dosage as well as duration of index treatment were observed (<xref ref-type="bibr" rid="bibr45-0269881112463470">Schirmbeck et al., 2011</xref>). However, the cross-sectional design and group differences at baseline regarding duration of illness, limited our results. Consequently we enlarged our sample and conducted this longitudinal follow-up investigation over a 12-month period with the primary endpoint of group-specific, intra-individual changes in OCS severity over time. We further assessed associations between comorbid OCS and other clinical variables, such as psychotic and depressive symptoms.</p>
</sec>
<sec id="section2-0269881112463470" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0269881112463470">
<title>Hypothesis, primary endpoint and analysis of power</title>
<p>We were interested in the longitudinal course of comorbid OCS in two pharmacologically diverse groups and hypothesized increases between group differences in OCS over time due to an aggravation of symptom severity within group I. The primary endpoint of this longitudinal investigation was defined as the comparison of changes in the Yale Brown Obsessive Compulsive Scale (YBOCS) over 12 months between the two groups. According to the described literature of beneficial or at least neutral effects of AMS and APZ on OCS (<xref ref-type="bibr" rid="bibr47-0269881112463470">Schirmbeck and Zink, 2012</xref>), we assumed no YBOCS increase within group II. We based our power analysis for sample size calculation (statistical power of 0.8, error of first order of α=0.05) on unpublished data from 21 CLZ-treated patients, who experienced a mean YBOCS increase of 4.8 ± 4.9 over a period of 2 years. This observation converges with positive correlations between the duration of CLZ treatment and OCS severity (<xref ref-type="bibr" rid="bibr47-0269881112463470">Schirmbeck and Zink, 2012</xref>). Since the incorporated sample size was moderate, we replaced the standard deviations by the upper limit of the corresponding confidence intervals (7.1) as a conservative estimation of the true standard deviation in the underlying population. An effect size of <italic>d</italic>=0.67 and necessary group size of at least <italic>n</italic>=20 was calculated. Analyses were performed using the statistical software G*Power (University of Trier) (<xref ref-type="bibr" rid="bibr18-0269881112463470">Erbfelder et al., 1996</xref>) to estimate necessary sample sizes.</p>
</sec>
<sec id="section4-0269881112463470">
<title>Participants</title>
<p>We screened 120 participants who were referred via their attending psychiatrist or administered as former or current patients at the Central Institute of Mental Health (CIMH). A sample of 75 patients met the pre-defined inclusion criteria and was included in the study: (1) lifetime diagnosis of a schizophrenia or schizoaffective disorder according to the diagnostic and statistical manual version IV research (DSM IV R); (2) monotherapy with either CLZ/OLZ or AMS/APZ; (3) stable antipsychotic medication and psychopathological states over a period of at least 2 weeks before baseline, as revealed by constant severity scores in Clinical Global Impression (CGI) and the Positive and Negative Syndrome Scale (PANSS). Exclusion criteria were the inability to provide informed consent, living at a distance of more than 50 km away from the CIMH, pregnancy, breast feeding, drug dependence other than nicotine, and combined antipsychotic treatment or augmentations with antidepressants other than reboxetine, bupropion and agomelatine at baseline. This investigation was approved by the ethical committee of the University of Heidelberg (2008-235N-MA) and was performed in complete agreement with the guidelines of good clinical practice. After providing the participants with a complete description of the study, written informed consent was obtained. At baseline patients were assigned into two observational groups according to their mode of antipsychotic treatment (group I: clozapine/olanzapine vs. group II: amisulpride/aripiprazole). Cross-sectional baseline analysis of a subsample of 70 patients are reported elsewhere (<xref ref-type="bibr" rid="bibr45-0269881112463470">Schirmbeck et al., 2011</xref>). We excluded patients from per protocol (PP) follow-up analyses when antipsychotic medication was changed or combination treatment was initiated. In these cases, baseline observations were carried forward (BOCF).</p>
</sec>
<sec id="section5-0269881112463470">
<title>Clinical assessments</title>
<p>Sociodemographic data on age, gender, education level, age of onset, duration of illness, and medical treatment were collected. Dosage and serum levels of antipsychotic agents were determined at baseline and after 12 months. Patients were assessed by a trained and certified rater (FS) using a comprehensive set of clinical rating scales: OCS were measured with the YBOCS, which has been validated for the assessment of OCS in schizophrenia (<xref ref-type="bibr" rid="bibr12-0269881112463470">de Haan et al., 2006</xref>; <xref ref-type="bibr" rid="bibr53-0269881112463470">Woody et al., 1995</xref>). Compulsions and obsessions are separately rated on five five-point (0–4) scale items (time, handicap, frequency, controllability, discomfort), yielding subtotal scores for compulsions and for obsessions (each ranging from 0–20). Ruminations or stereotypic thoughts clearly related to the patient’s delusions, or repetitive ritualized behaviour such as mannerisms or posturing were attributed to the primary psychotic condition and not to comorbid OCS. Patients also filled out a self-rating questionnaire (Hamburger Zwangsinventar HZI-K) which assesses subclinical and clinically relevant obsessive and compulsive symptoms (<xref ref-type="bibr" rid="bibr27-0269881112463470">Klepsch et al., 1993</xref>). The subscales include checking, washing, ordering and counting behaviour as well as obsessions.</p>
<p>Current severity of the psychotic disorder was measured with the PANSS. We further applied the Calgary Depression Scale for Schizophrenia (CDSS), the CGI and the Personal and Social Performance Scale (PSP). Side effects of pharmacological treatment were assessed using the Antipsychotic Non-Neurological Side Effects Rating Scale (ANNSERS) and the Extrapyramidal motoric symptom scale (EPS). All clinical rating scales were administered at baseline and after 12 months.</p>
</sec>
<sec id="section6-0269881112463470">
<title>Statistical analysis</title>
<p>The statistical analysis was performed using the Statistical package for Social Sciences (SPSS version 18.0). We applied histograms and the Kolmogorov–Smirnov test to test for normal distribution. Non-normal distributed parameters were compared between groups with non-parametric Mann–Whitney <italic>U</italic> tests. Sociodemographic and psychopathological characteristics were compared between treatment groups using student <italic>t</italic>-tests and Chi<sup>2</sup> tests. Hypothesized differential between-group changes over a 12-month period were investigated with a repeated measure analysis of variances (rmANOVA) and <italic>post hoc</italic> paired <italic>t</italic>-test. Regarding these longitudinal comparisons, we calculated PP analyses including patients with comprehensive data for both time points of assessment. In order to account for patients who dropped out at follow-up we calculated separate analyses with baseline date carried forward (BOCF samples). Non-parametric correlation analyses were performed between OCS severity (YBOCS) and other clinical variables such as psychosis (PANSS), psychosocial functioning (PSP, CGI) and depression (CDSS).</p>
</sec>
</sec>
<sec id="section7-0269881112463470" sec-type="results">
<title>Results</title>
<sec id="section8-0269881112463470">
<title>Sociodemographic characteristics and clinical assessments</title>
<p>In total, 75 patients with schizophrenia (<italic>N</italic>=73) or schizoaffective (<italic>N</italic>=2) disorder according to DSM IV R were investigated. The two groups did not significantly differ regarding age, gender, years of education, and estimated premorbid verbal intelligence. Furthermore, severity of psychotic syndromes (PANSS positive, negative, global psychopathology (GPP)), affective comorbidity (CDSS), and general severity of illness (CGI) as well as general functioning (PSP) did not differ between groups. However, patients in group I showed significantly longer duration of illness (T=2.721; <italic>p</italic>=.008) (<xref ref-type="table" rid="table1-0269881112463470">Table 1</xref>). Comorbidity with non-psychiatric disorders was rarely found and did not differ between groups. Within group I, 26 patients were treated with CLZ, 15 with OLZ, while in group II, 16 received AMS and 18 received APZ. Duration of treatment at baseline significantly differed between groups (see <xref ref-type="table" rid="table2-0269881112463470">Table 2</xref>). Mean current doses were within the recommended and commonly used limits; however, group I showed higher chlorpromazine-equivalent doses as calculated according to <xref ref-type="bibr" rid="bibr21-0269881112463470">Gardner et al. (2011)</xref>. Adherence was validated by assessments of serum levels at the two time-points of assessment (see <xref ref-type="table" rid="table2-0269881112463470">Table 2</xref>).</p>
<table-wrap id="table1-0269881112463470" position="float">
<label>Table 1.</label>
<caption>
<p>Sociodemographic and clinical characteristics.</p>
</caption>
<graphic alternate-form-of="table1-0269881112463470" xlink:href="10.1177_0269881112463470-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Group I (CLZ/OLZ)</th>
<th align="left">Group II (AMS/APZ)</th>
<th align="left">Between-group differences</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4"><bold>Sociodemographics</bold></td>
</tr>
<tr>
<td>N</td>
<td>41 (26/15)</td>
<td>34 (16/18)</td>
<td/>
</tr>
<tr>
<td>Age</td>
<td>37.4±10.2</td>
<td>36.1±10.7</td>
<td>T=0.507 <italic>p</italic>&gt; .05</td>
</tr>
<tr>
<td>Male/female ratio</td>
<td>30:11</td>
<td>23:11</td>
<td>χ<sup>2</sup>=0.274 <italic>p</italic>&gt; .05</td>
</tr>
<tr>
<td>Age of onset</td>
<td>26.4±6.3</td>
<td>29.9±8.5</td>
<td>T=−1.991 <italic>p</italic>&gt; .05</td>
</tr>
<tr>
<td>Duration of illness</td>
<td>11.3± 9.0</td>
<td>6.3±6.5</td>
<td><bold>T=2.721 <italic>p</italic>= .008</bold></td>
</tr>
<tr>
<td>Education in years</td>
<td>10.9±1.8</td>
<td>10.9±1.8</td>
<td>T=−0.028 <italic>p</italic>&gt; .05</td>
</tr>
<tr>
<td>Premorbid intelligence</td>
<td>103.9±15.1</td>
<td>103.5±13.7</td>
<td>T=0.100 <italic>p</italic>&gt; .05</td>
</tr>
<tr>
<td colspan="4"><bold>General Functioning</bold></td>
</tr>
<tr>
<td>CGI</td>
<td>3.6±0.7</td>
<td>3.2±0.7</td>
<td>χ<sup>2</sup>=6.250 p&gt;.05</td>
</tr>
<tr>
<td>PSP</td>
<td>67.2±6.3</td>
<td>70.1±7.3</td>
<td>T=−1.834 p&gt;.05</td>
</tr>
<tr>
<td colspan="4"><bold>PANSS</bold></td>
</tr>
<tr>
<td> Positive Scale</td>
<td>14.2±2.9</td>
<td>13.0±2.7</td>
<td>T=1.920 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td> Negative Scale</td>
<td>16.9±4.7</td>
<td>15.3±5.3</td>
<td>T=1.367 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td> General Psychopathology</td>
<td>34.9±4.9</td>
<td>32.9±5.2</td>
<td>T=1.722 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td><bold>CDSS</bold></td>
<td>1.5±1.8</td>
<td>1.6±2.4</td>
<td>T=−0.264 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td><bold>ANNSERS</bold></td>
<td>5.3±3.3</td>
<td>1.7±2.4</td>
<td><bold>T=5.274 <italic>p</italic>&lt;.001</bold></td>
</tr>
<tr>
<td><bold>EPS</bold></td>
<td>1.2±1.2</td>
<td>0.3±0.9</td>
<td><bold>T=3.338 <italic>p</italic> = .001</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881112463470">
<p>Sociodemographic characteristics and clinical assessments: the table summarizes group characteristics and evidence for group-dependent differences regarding sample size, age, gender, age at first psychotic manifestation, duration of illness, education in years, premorbid intelligence, general psychosocial functioning and psychopathology regarding psychotic syndromes and mood, as well as pharmacological side-effects.</p>
</fn>
<fn id="table-fn2-0269881112463470">
<p>AMS: Amisulpride; APZ: Aripiprazole; CLZ: Clozapine; OLZ: Olanzapine; CGI: Clinical global impression; PSP: Personal and social performance scale; PANSS: Positive and negative syndrome scale; CDSS: Calgary depression scale for schizophrenia; ANNSERS: Antipsychotic Non-Neurological side effects rating scale; EPS: Extrapyramidale motoric symptom scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0269881112463470" position="float">
<label>Table 2.</label>
<caption>
<p>Psychopharmacological treatment: duration of treatment with index medication, dosage and serum levels.</p>
</caption>
<graphic alternate-form-of="table2-0269881112463470" xlink:href="10.1177_0269881112463470-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="2">Group I<hr/></th>
<th align="left" colspan="2">Group II<hr/></th>
<th align="left">Between-group differences</th>
</tr>
<tr>
<th align="left">Baseline</th>
<th align="left">CLZ (<italic>N</italic>=26)</th>
<th align="left">OLZ (<italic>N</italic>=15)</th>
<th align="left">AMS (<italic>N</italic>=16)</th>
<th align="left">APZ (<italic>N</italic>=18)</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of treatment (years)</td>
<td>7.9±6.8</td>
<td>3.5±3.8</td>
<td>1.0±1.3</td>
<td>1.7±1.9</td>
<td>T=4.889 <italic>p</italic>&lt;.001</td>
</tr>
<tr>
<td>Dosage (mg/day)</td>
<td>342.3±158.1</td>
<td>17.6±7.4</td>
<td>506.2±232.3</td>
<td>19.2±6.9</td>
<td/>
</tr>
<tr>
<td>CPZ (mg(day)</td>
<td>513.4±237.1</td>
<td>527.5±223.4</td>
<td>435.4±200</td>
<td>384±132</td>
<td>T=2.335 <italic>p</italic>=.022</td>
</tr>
<tr>
<td>Serum levels</td>
<td>0.32±0.24 mg/L</td>
<td>35.7±14.3 µg/L</td>
<td>94.4±115.8 µg/L</td>
<td>265.4±170.5 µg/L</td>
<td/>
</tr>
<tr>
<td colspan="6"><hr/></td>
</tr>
<tr>
<th align="left">12 months follow-up</th>
<th align="left">CLZ (<italic>N</italic>=18)</th>
<th align="left">OLZ (<italic>N</italic>=10)</th>
<th align="left">AMS (<italic>N</italic>=9)</th>
<th align="left">APZ (<italic>N</italic>=13)</th>
<th/>
</tr>
<tr>
<td colspan="6"><hr/></td>
</tr>
<tr>
<td>Dosage (mg/day)</td>
<td>315.3±162.1</td>
<td>14.8±7.8</td>
<td>337.5±118.8</td>
<td>14.2±7.0</td>
<td/>
</tr>
<tr>
<td>CPZ (mg/day)</td>
<td>472.9±243.1</td>
<td>445.3±234.1</td>
<td>290.3±102.1</td>
<td>284.6±140.5</td>
<td>T=3.310 <italic>p</italic>=.002</td>
</tr>
<tr>
<td>Serum levels</td>
<td>290±250 mg/L</td>
<td>38.1±38.9 µg/L</td>
<td>90.5±91.3 µg/L</td>
<td>178.4±137.4 µg/L</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0269881112463470">
<p>Pharmacological treatment: means and standard deviations of group-specific properties and between-group differences are depicted for duration of treatment with index medication, dosage, serum levels.</p>
</fn>
<fn id="table-fn4-0269881112463470">
<p>AMS: Amisulpride; APZ: Aripiprazole; CLZ: Clozapine; OLZ: Olanzapine; CPZ: Chlorpromazine-equivalent values.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>At baseline, 31 group I and 11 group II patients reported the occurrence of any OCS during the last week. However, only three group II patients (8.8%) reported OCS with a YBOCS score higher than 8, while 28 (68.3%) patients of group I scored above 8 with a mean severity score of 12.4 (S.D.=8.9). A subgroup of 13 (46.4%) of these 28 patients had a total score of 16 or more, representing clinically meaningful illness severity.</p>
<p>During the period of interest several events caused dropouts (see consort flow diagram in <xref ref-type="fig" rid="fig1-0269881112463470">Figure 1</xref>). Dropouts did not significantly differ from completers regarding most sociodemographic or psychopathologic variables (see <xref ref-type="table" rid="table3-0269881112463470">Table 3</xref>). Within dropouts, the number of patients who reported OCS at baseline (12 individuals from group I and four individuals from group II) did also not significantly differ from reported frequencies within completers. However, patients who dropped out of group II showed higher PANSS negative scores as well as higher illness severity as measured with the CGI, compared with completers.</p>
<fig id="fig1-0269881112463470" position="float">
<label>Figure 1.</label>
<caption>
<p>Consort diagram of sample flow.</p>
<p>AMS: Amisulpride; APZ: Aripiprazole; CLZ: Clozapine; OLZ: Olanzapine.</p>
</caption>
<graphic xlink:href="10.1177_0269881112463470-fig1.tif"/>
</fig>
<table-wrap id="table3-0269881112463470" position="float">
<label>Table 3.</label>
<caption>
<p>Group-specific comparisons between dropouts and completers.</p>
</caption>
<graphic alternate-form-of="table3-0269881112463470" xlink:href="10.1177_0269881112463470-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="3">Group I<hr/></th>
<th align="left" colspan="3">Group II<hr/></th>
</tr>
<tr>
<th/>
<th align="left">Dropouts</th>
<th align="left">Completers</th>
<th align="left">Between-group differences</th>
<th align="left">Dropout</th>
<th align="left">Completers</th>
<th align="left">Between-group differences</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="7"><bold>Sociodemographics</bold></td>
</tr>
<tr>
<td><italic>N</italic></td>
<td>13</td>
<td>28</td>
<td/>
<td>12</td>
<td>22</td>
<td/>
</tr>
<tr>
<td>Age</td>
<td>35.0±9.7</td>
<td>38.4±10.2</td>
<td>T=−0.994 <italic>p</italic>&gt;.05</td>
<td>34.1±10.6</td>
<td>37.2±10.8</td>
<td>T=−0.816 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td>Male:female ratio</td>
<td>8:5</td>
<td>22:6</td>
<td>χ<sup>2</sup>=1.398 <italic>p</italic>&gt;.05</td>
<td>8:4</td>
<td>15:7</td>
<td>χ<sup>2</sup>=0.008 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td>Age of onset</td>
<td>27.4±8.0</td>
<td>25.8±5.3</td>
<td>T=0.639 <italic>p</italic>&gt;.05</td>
<td>28.7±8.6</td>
<td>30.9±9.0</td>
<td>T=−0.652 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td>Duration of illness</td>
<td>7.8±6.4</td>
<td>13.0±9.6</td>
<td>T=−1.797 <italic>p</italic>&gt;.05</td>
<td>4.6± 3.4</td>
<td>7.1±7.6</td>
<td>T=−1.269 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td>Education in years</td>
<td>10.5±1.8</td>
<td>11.0±1.8</td>
<td>T=−0.922 <italic>p</italic>&gt;.05</td>
<td>10.6±1.9</td>
<td>11.1±1.7</td>
<td>T=-0.782 p&gt;.05</td>
</tr>
<tr>
<td>Premorbid intelligence</td>
<td>101.8±14.1</td>
<td>105.3±15.4</td>
<td>T=−0.690 <italic>p</italic>&gt;.05</td>
<td>100.3±15.1</td>
<td>105.7±13.7</td>
<td>T=-1.461 p&gt;.05</td>
</tr>
<tr>
<td colspan="7"><bold>General Functioning</bold></td>
</tr>
<tr>
<td>CGI</td>
<td>3.7±0.6</td>
<td>3.6±0.8</td>
<td>U=178.500 <italic>p</italic>&gt;.05</td>
<td>3.7±0.4</td>
<td>2.9±0.7</td>
<td><bold>U=49.500 <italic>p</italic>=.001</bold></td>
</tr>
<tr>
<td>PSP</td>
<td>65.5±6.5</td>
<td>67.5±6.6</td>
<td>T=−0.944 <italic>p</italic>&gt;.05</td>
<td>67.1±5.6</td>
<td>71.9±7.5</td>
<td>T=−1.940 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td colspan="7"><bold>PANSS</bold></td>
</tr>
<tr>
<td> Positive Scale</td>
<td>15.4±3.0</td>
<td>13.7±2.7</td>
<td>T=1.786 <italic>p</italic>&gt;.05</td>
<td>14.2±2.2</td>
<td>12.4±2.8</td>
<td>T=1.930 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td> Negative Scale</td>
<td>17.5±5.1</td>
<td>16.6±4.6</td>
<td>T=0.512 <italic>p</italic>&gt;.05</td>
<td>18.6±5.4</td>
<td>13.6±4.3</td>
<td><bold>T=2.955 <italic>p</italic> =.006</bold></td>
</tr>
<tr>
<td> General Psychopathology</td>
<td>36.2±5.5</td>
<td>34.3±4.6</td>
<td>T=1.167 <italic>p</italic>&gt;.05</td>
<td>35.2±4.3</td>
<td>31.6±5.3</td>
<td>T=2.017 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td><bold>CDSS</bold></td>
<td>1.5±1.8</td>
<td>1.5±1.9</td>
<td>T=0.120 <italic>p</italic>&gt;.05</td>
<td>1.7±1.9</td>
<td>1.6±2.7</td>
<td>T=0.085 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td colspan="7"><bold>YBOCS</bold></td>
</tr>
<tr>
<td>Compulsions</td>
<td>7.9±3.6</td>
<td>5.7±5.2</td>
<td>U=142.000 <italic>p</italic>&gt;.05</td>
<td>2.2±3.2</td>
<td>1.4±2.8</td>
<td>U=116.500 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td>Obsessions</td>
<td>7.1±4.5</td>
<td>5.4±4.6</td>
<td>U=148.000 <italic>p</italic>&gt;.05</td>
<td>1.1±2.7</td>
<td>0.8±2.0</td>
<td>U=127.500 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td>Total</td>
<td>15.1±7.6</td>
<td>11.1±9.3</td>
<td>U=131.500 <italic>p</italic>&gt;.05</td>
<td>3.2±5.5</td>
<td>2.2±3.8</td>
<td>U=124.000 <italic>p</italic>&gt;.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0269881112463470">
<p>Within-group comparisons between dropouts and completers for sociodemographic characteristics and clinical assessments. The table summarizes evidence for differences regarding age, gender, age at first psychotic manifestation, duration of illness, education in years, premorbid intelligence, general psychosocial functioning and psychopathology regarding psychotic syndromes, mood and obsessive-compulsive symptoms.</p>
</fn>
<fn id="table-fn6-0269881112463470">
<p>AMS: Amisulpride; APZ: Aripiprazole; CLZ: Clozapine; OLZ: Olanzapine; CGI: Clinical global impression; PSP: Personal and social performance scale; PANSS: Positive and negative syndrome scale; CDSS: Calgary depression scale for schizophrenia; YBOCS: Yale Brown Obsessive Compulsive Scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Within the 12-month observation period, all comorbid group I patients reported persisting or increasing OCS with the exception of one patient, who showed substantial improvement (YBOCS-Score -4) and no <italic>de novo</italic> development occurred. In three cases, selective serotonin reuptake inhibitors (SSRIs): citalopram, escitalopram, paroxetine) were added by their attending psychiatrist. In spite of therapeutic doses and treatment periods of more than 12 weeks, all of them reported an increase in OCS severity at follow-up. Contrary, within group II, no <italic>de novo</italic> onset or aggravation of comorbid OCS was found. The initially low OCS severity scores further decreased. <xref ref-type="table" rid="table4-0269881112463470">Table 4</xref> shows YBOCS and HZI scores at baseline and after 12 months (follow-up) under PP conditions.</p>
<table-wrap id="table4-0269881112463470" position="float">
<label>Table 4.</label>
<caption>
<p>Between-group comparison of obsessive–compulsive severity.</p>
</caption>
<graphic alternate-form-of="table4-0269881112463470" xlink:href="10.1177_0269881112463470-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Group I (<italic>N</italic>=28) (CLZ/OLZ)</th>
<th align="left">Group II (<italic>N</italic>=22) (AMS/APZ)</th>
<th align="left">Between-group differences</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4"><bold>Baseline</bold></td>
</tr>
<tr>
<td colspan="4">YBOCS</td>
</tr>
<tr>
<td> Obsessions</td>
<td>5.4±4.6</td>
<td>0.8±2.1</td>
<td><bold>U=135.0 <italic>p</italic>&lt;.001</bold></td>
</tr>
<tr>
<td> Compulsions</td>
<td>5.7±5.2</td>
<td>1.4±2.8</td>
<td><bold>U=164.5 <italic>p</italic>=.002</bold></td>
</tr>
<tr>
<td> Total Score</td>
<td>11.1±9.3</td>
<td>2.2±3.8</td>
<td><bold>U=140.0 <italic>p</italic>&lt;.001</bold></td>
</tr>
<tr>
<td colspan="4">HZI</td>
</tr>
<tr>
<td> Checking</td>
<td>4.8±2.9</td>
<td>2.3±2.1</td>
<td><bold>U=124.5 <italic>p</italic>=.004</bold></td>
</tr>
<tr>
<td> Washing</td>
<td>1.4±1.2</td>
<td>1.3±1.3</td>
<td>U=247.5 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td> Ordering</td>
<td>2.6±1.5</td>
<td>2.1±1.5</td>
<td>U=197.5 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td> Counting</td>
<td>1.7±1.9</td>
<td>0.4±0.8</td>
<td><bold>U=136.0 <italic>p</italic>=.006</bold></td>
</tr>
<tr>
<td> Obsessions</td>
<td>2.3±1.9</td>
<td>2.2±1.6</td>
<td>U=249.0 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td colspan="4"><bold>12 months</bold></td>
</tr>
<tr>
<td colspan="4">YBOCS</td>
</tr>
<tr>
<td> Obsessions</td>
<td>6.0±4.8</td>
<td>0.5±1.7</td>
<td><bold>U=122.0 <italic>p</italic>&lt;.001</bold></td>
</tr>
<tr>
<td> Compulsions</td>
<td>5.9±5.4</td>
<td>0.4±0.9</td>
<td><bold>U=137.5 <italic>p</italic>&lt;.001</bold></td>
</tr>
<tr>
<td> Total Score</td>
<td>12.0±9.9</td>
<td>0.9±1.8</td>
<td><bold>U=113.5 <italic>p</italic>&lt;.001</bold></td>
</tr>
<tr>
<td colspan="4">HZI</td>
</tr>
<tr>
<td> Checking</td>
<td>4.9±2.7</td>
<td>2.4±1.7</td>
<td><bold>U=112.5 <italic>p</italic>=.001</bold></td>
</tr>
<tr>
<td> Washing</td>
<td>1.6±1.5</td>
<td>1.3±1.2</td>
<td>U=221.0 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td> Ordering</td>
<td>2.4±1.8</td>
<td>1.9±1.8</td>
<td>U=205.5 <italic>p</italic>&gt;.05</td>
</tr>
<tr>
<td> Counting</td>
<td>1.7±2.2</td>
<td>0.6±1.3</td>
<td><bold>U=152.5 <italic>p</italic>=.015</bold></td>
</tr>
<tr>
<td> Obsessions</td>
<td>2.5±2.3</td>
<td>1.3±1.6</td>
<td><bold>U=158.5 <italic>p</italic>=.032</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0269881112463470">
<p>Mann-Whitney-U-Test for between-group comparison of OCS severity at baseline and 12 months follow-up: means and standard deviations of YBOCS-scales are reported. AMS: Amisulpride; APZ: Aripiprazole; CLZ: Clozapine; HZI: Hamburger Zwangsinventar; OLZ: Olanzapine; YBOCS: Yale Brown Obsessive Compulsive Scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-0269881112463470">
<title>Longitudinal course of obsessive–compulsive symptoms</title>
<p>The repeated measure ANOVA documented significant interaction effects between the variables, group, and time for the subscale compulsion (F=6.355, <italic>p</italic>=0.023) and the YBOCS total score (F=8.179, <italic>p</italic>=0.006), but not for obsessions (see <xref ref-type="fig" rid="fig2-0269881112463470">Figure 2</xref>). Between-group effects reached statistical significance for all YBOCS variables (obsessions: F=23.669, <italic>p</italic>&lt;0.001; compulsions: F=17.801 <italic>p</italic>&lt;0.001 and total score: F=22.758, <italic>p</italic>&lt;0.001).</p>
<fig id="fig2-0269881112463470" position="float">
<label>Figure 2.</label>
<caption>
<p>Group-dependent changes in YBOCS scores over the 12 month follow-up period; per protocol analyses. Repeated measure analysis of variance (ANOVA) were calculated for the YBOCS total score, the subscales ‘obsessions’ and ‘compulsions’: *significant interaction effects, <italic>p</italic>&lt;0.05; **significant interaction effects, <italic>p</italic> &lt; 0.01. YBOCS: Yale Brown Obsessive Compulsive Scale.</p>
</caption>
<graphic xlink:href="10.1177_0269881112463470-fig2.tif"/>
</fig>
<p>Group-specific <italic>post hoc</italic> paired <italic>t</italic>-tests showed significant OCS reduction within group II over time for the subscale compulsions (T=2.236, <italic>p</italic>=0.036) and a trend for the YBOCS total score (T=2.030, <italic>p</italic>=0.055), but not for the subscale obsessions (T=1.000, <italic>p</italic>&gt;0.05). Within group I, changes in the YBOCS scales did not reach statistical significance regarding compulsions and obsessions but showed a trend towards increasing YBOCS total scores (T=−1.949, <italic>p</italic>=0.062). The initial YBOCS differences between groups increased over the 12-month follow-up period from Δ<sub>YBOCS</sub>=8.9 to 11.1 (PP).</p>
<p>The additional BOCF perspective (<italic>n</italic>=75) showed similar results with significant group×time interaction effects for the subscale compulsions (F=5.867, <italic>p</italic>=0.025) and the YBOCS total score (F=7.761, <italic>p</italic>= .007), as well as significant between-group differences for all three YBOCS variables (obsessions: F=40.553, <italic>p</italic>&lt;0.001; compulsions: F=31.827 <italic>p</italic>&gt;0.001; total: F=40.029, <italic>p</italic>&lt;0.001). <italic>Post hoc</italic> paired <italic>t</italic>-tests revealed significant changes within group II for the subscale compulsions (T=2.166, <italic>p</italic>=0.038). No YBOCS scores changed significantly within group I and YBOCS differences between groups increased over the 12-month follow-up period from Δ<sub>YBOCS</sub>=9.8 to 11.3.</p>
<p>Furthermore, we calculated repeated measure analyses for the HZI self-report questionnaire assessing subclinical and clinically relevant obsessions and compulsions. Results revealed significant group effects for the subscales checking (F=12.182, <italic>p</italic>=0.001) and counting (F=6.360, <italic>p</italic>=0.015). A significant group×time interaction effect was found for the subscale measuring obsessions (F=6.230, <italic>p</italic>=0.016) with significant reduction within group II over time (paired <italic>t</italic>-test: 2.769, <italic>p</italic>=0.012).</p>
<p>As the two groups showed significant differences in their illness duration, we integrated this factor as a covariate. ANCOVAs showed that duration of illness did not significantly contribute to presented OCS as measured with the three YBOCS scales or HZI subscales. All reported PP and BOCF results remained significant.</p>
</sec>
<sec id="section10-0269881112463470">
<title>Longitudinal course of psychotic symptoms</title>
<p>The PP evaluation of psychotic symptoms over time using a rmANOVA showed neither significant group×time interaction effects nor significant time effects for the PANSS total score (F=3.217, <italic>p</italic>&gt;0.05 / F=1.783, <italic>p</italic>&gt;0.05), the subscale positive symptoms (F=0.168, <italic>p</italic>&gt;0.05 / F=0.065, <italic>p</italic>&gt;0.05), the subscale negative symptoms (F=2.288, <italic>p</italic>&gt;0.05 / F=0.783, <italic>p</italic>&gt;0.05), or the subscale GPP (F=3.898, <italic>p</italic>&gt;0.05 /F=3.252, <italic>p</italic>&gt;0.05).</p>
<p>Group-specific <italic>post hoc</italic> paired <italic>t</italic>-tests revealed no significant changes over time, except for a significant reduction in the GPP subscale within group II (T=2.151, <italic>p</italic>=0.043).</p>
<p>Again, BOCF analyses showed similar results and revealed no significant group×time interaction effects nor significant time effects for the PANSS total score (F=3.001, <italic>p</italic>&gt;0.05 / F=1.595, <italic>p</italic>&gt;0.05), positive symptoms (F=0.164, <italic>p</italic>&gt;0.05 / F=0.059, <italic>p</italic>&gt;0.05), negative symptoms (F=2.186, <italic>p</italic>&gt;0.05 / F=0.691, <italic>p</italic>&gt;0.05), or the subscale GPP (F=3.544, <italic>p</italic>&gt;0.05 /F=2.919, <italic>p</italic>&gt;0.05).</p>
</sec>
<sec id="section11-0269881112463470">
<title>Correlations between OCS and other clinical variables</title>
<p>At baseline, we did not observe any significant correlations between OCS severity (YBOCS total score) and schizophrenia symptoms (PANSS), clinical global impression (CGI), social performance (PSP), nor affective comorbidities (CDSS) within group I. However, within group II OCS severity correlated significantly with the PANSS negative subscale (ρ=0.36, <italic>p</italic>=0.018) and the GPP subscale (ρ=0.33, <italic>p</italic>=0.028).</p>
<p>After 12 months, significant correlations for group I were found between OCS severity and the PANSS negative (ρ=0.37, <italic>p</italic>=0.030) and GPP subscales (ρ=0.46, <italic>p</italic>=0.007), as well as with depressive symptoms (CDSS: ρ=0.37, <italic>p</italic>=0.028). Within group II, OCS severity again correlated with the PANSS negative subscale (ρ=0.40, <italic>p</italic>=0.031).</p>
<p>In addition to these cross-sectional evaluations, we calculated correlations between time-dependent changes in the YBOCS total score (difference between scores at 12 months and baseline), and changes in psychometric scales mentioned above. Overall, changes in OCS severity were significantly associated with changes in the PANSS subscale General Psychopathology (ρ=0.57, <italic>p</italic>=0.005).</p>
</sec>
</sec>
<sec id="section12-0269881112463470" sec-type="discussion">
<title>Discussion</title>
<p>This study investigated the longitudinal course of OCS in schizophrenia patients. We found significantly different courses of OCS severity over a period of 12 months in two well-defined groups, which were classified according to their mode of antipsychotic monotherapy.</p>
<sec id="section13-0269881112463470">
<title>The longitudinal course of OCS severity</title>
<p>Within the 12-month observation period, repeated measure analyses revealed significant group effects for all YBOCS variables, as well as group×time interaction effects for compulsions and the total score. These results suggest differential pharmacodynamic effects on OCS severity. While all but one of the individuals treated with CLZ/OLZ who had reported OCS at baseline showed persisting or increasing OCS, patients within group II showed further decrease of the initially low YBOCS compulsion scores. Although we observed a trend towards increasing OCS within group I, we did not find the hypothesized significant aggravation of OCS within this group. It is likely that possible OCS induction or aggravation does not proceed linearly over time, and that the differential course of OCS between the two groups might have been stronger when looking at the first years after CLZ/OLZ initiation. While other authors reported large fluctuations of comorbid OCS and persistence in only a minority (13.4%) of first-admission schizophrenia patients (<xref ref-type="bibr" rid="bibr15-0269881112463470">de Haan et al., 2011</xref>), our results suggest that the subgroup of patients with second-onset OCS will show stable persisting or increasing symptoms under CLZ/OLZ treatment. These findings hint towards an ongoing pro-obsessive effect of antiserotonergic SGAs when compared with more pronounced dopaminergic SGAs, and stand in line with previous research proposing differential effects of SGAs (<xref ref-type="bibr" rid="bibr47-0269881112463470">Schirmbeck and Zink, 2012</xref>).</p>
<p>Cognitive behavioural therapy, the treatment of first choice in OCD (<xref ref-type="bibr" rid="bibr28-0269881112463470">Koran et al., 2007</xref>; <xref ref-type="bibr" rid="bibr42-0269881112463470">Rosa-Alcazar et al., 2008</xref>), was not provided to any of our comorbid patients during the study. This was most likely due to a lack of awareness, or the anticipation of psychotic exacerbations.</p>
<p>The initiated anti-obsessive treatment with SSRIs in only three cases might also reflect a reduced clinical awareness for OCS in schizophrenia patients. In accordance, <xref ref-type="bibr" rid="bibr34-0269881112463470">Mukhopadhaya et al. (2009)</xref> reported 50% undetected comorbid cases in their study. We did not observe marked pharmacokinetic effects of SSRI treatment on CLZ serum levels. Therefore, the anti-obsessive efficacy of SSRI treatment in these individuals seemed limited, a finding which has been reported in schizophrenia with comorbid OCS before (<xref ref-type="bibr" rid="bibr13-0269881112463470">de Haan et al., 1999</xref>; <xref ref-type="bibr" rid="bibr31-0269881112463470">Lykouras et al., 2003</xref>; <xref ref-type="bibr" rid="bibr34-0269881112463470">Mukhopadhaya et al., 2009</xref>). Nevertheless, other studies report beneficial effects of additional SSRI treatment, though always recommending careful monitoring for adverse effects and drug interactions with this treatment combination (<xref ref-type="bibr" rid="bibr22-0269881112463470">Hwang et al., 2009</xref>). It is therefore possible that the intercurrent treatment with SSRI in group I patients has prevented further deterioration of OCS, thereby leading to an underestimation of quantitative effects.</p>
<p>While the induction of secondary OCS might be considered one amongst several adverse events of CLZ (<xref ref-type="bibr" rid="bibr2-0269881112463470">Asenjo Lobos et al., 2010</xref>; <xref ref-type="bibr" rid="bibr47-0269881112463470">Schirmbeck and Zink, 2012</xref>), the general importance of CLZ as a necessary and indispensable part of the antipsychotic armament (<xref ref-type="bibr" rid="bibr23-0269881112463470">Joober and Boksa, 2010</xref>; <xref ref-type="bibr" rid="bibr25-0269881112463470">Kang and Simpson, 2010</xref>) should not be derogated. As the antipsychotic of first choice in treatment-resistant schizophrenia (<xref ref-type="bibr" rid="bibr2-0269881112463470">Asenjo Lobos et al., 2010</xref>; <xref ref-type="bibr" rid="bibr24-0269881112463470">Kane et al., 1988</xref>; <xref ref-type="bibr" rid="bibr33-0269881112463470">McEvoy et al., 2006</xref>), this substance embarks important anti-suicidal effects and was associated with the lowest mortality rates in the large, naturalistic FIN11-study (<xref ref-type="bibr" rid="bibr50-0269881112463470">Tiihonen et al., 2009</xref>).</p>
<p>The significant reduction of OCS severity within group II supports hypothesized beneficial effects of APZ on OCS. Previous findings suggested that AMS would be at least neutral regarding OCS comorbidity due to its exclusive dopaminergic mode of action (<xref ref-type="bibr" rid="bibr26-0269881112463470">Kim et al., 2008</xref>), while the partial dopaminergic and serotonergic agonism of APZ was proposed to exert anti-obsessive effects most likely via 5HT1A (<xref ref-type="bibr" rid="bibr7-0269881112463470">Chang et al., 2008</xref>; <xref ref-type="bibr" rid="bibr17-0269881112463470">Englisch et al., 2009</xref>; <xref ref-type="bibr" rid="bibr35-0269881112463470">Muscatello et al., 2011</xref>). Furthermore, augmentation studies with SGAs in SSRI-treatment-resistant obsessive–compulsive disorder (OCD) reported beneficial effects for APZ and risperidone, but not for OLZ or CLZ (<xref ref-type="bibr" rid="bibr4-0269881112463470">Bloch et al., 2006</xref>; <xref ref-type="bibr" rid="bibr16-0269881112463470">Dold et al., 2011</xref>; <xref ref-type="bibr" rid="bibr35-0269881112463470">Muscatello et al., 2011</xref>).</p>
<p>However, our finding is limited by the small sample of comorbid patients within this group. Further randomized controlled trails involving APZ and AMS with larger sample sizes and OCS as the primary endpoint are needed to investigate the validity of the observed OCS reduction.</p>
<p>The hypothesis that serotonergic mechanisms underlie the observed course of OCS severity over time stands in line with current pathogenetic theories of OCD. However, since the involved SGAs also differ regarding histaminergic and cholinergic effects, a direct link to specific pathogenetic mechanisms of obsessions and compulsions cannot be established. It is open to speculation as to whether differential effects within the glutamatergic neurotransmission might be involved. This hypothesis was stimulated by recent evidence suggesting that specific genetic properties might dispose schizophrenic patients to the development of secondary OCS during treatment with SGAs. One candidate polymorphism has recently been located in the gene <italic>SLC1A1</italic> (former nomenclature EAAC1: excitatory amino acid carrier 1) encoding the neuronal glutamate transporter (<xref ref-type="bibr" rid="bibr29-0269881112463470">Kwon et al., 2009</xref>), but a replication study failed to find this effect (<xref ref-type="bibr" rid="bibr46-0269881112463470">Schirmbeck et al., 2012</xref>). In perspective, investigating the interactions of several genetic markers might help to understand the pathomechanisms of SGA-induced OCS (<xref ref-type="bibr" rid="bibr43-0269881112463470">Ryu et al., 2011</xref>).</p>
</sec>
<sec id="section14-0269881112463470">
<title>Interaction of OCS and general psychopathological state (PANSS, CDSS)</title>
<p>Previous findings concerning the interaction of comorbid OCS and other clinical variables in schizophrenia have been inconclusive. A recent meta-analysis by <xref ref-type="bibr" rid="bibr9-0269881112463470">Cunill et al. (2009)</xref> reported more severe global, positive, and negative symptoms if OCS were present. One finding that has been repeatedly reported is the association between comorbid OCS and depressive symptoms in schizophrenic patients (<xref ref-type="bibr" rid="bibr11-0269881112463470">de Haan et al., 2005</xref>; <xref ref-type="bibr" rid="bibr32-0269881112463470">Lysaker and Whitney, 2009</xref>; <xref ref-type="bibr" rid="bibr37-0269881112463470">Ohoyama et al., 2011</xref>; <xref ref-type="bibr" rid="bibr48-0269881112463470">Sevincok et al., 2007</xref>), but the direction of causality remains unclear. Our analyses at baseline did not find significant correlations between OCS severity and other psychopathological variables. However, 12 months later, OCS severity was significantly associated with PANSS GPP and negative symptoms and also with more depressive symptoms within group I. These results confirm mentioned data showing that schizophrenia patients who suffer from comorbid OCS are also more prone to suffer from affective symptoms and to report more negative symptoms and higher overall symptom severity. Further longitudinal studies starting with at-risk mental state patients might be able to work out the causal directions of this association (<xref ref-type="bibr" rid="bibr20-0269881112463470">Fontenelle et al., 2011</xref>; <xref ref-type="bibr" rid="bibr36-0269881112463470">Niendam et al., 2009</xref>).</p>
</sec>
<sec id="section15-0269881112463470">
<title>Limitations</title>
<p>Within the broad and heterogeneous spectrum of comorbid OCS in schizophrenia (<xref ref-type="bibr" rid="bibr47-0269881112463470">Schirmbeck and Zink, 2012</xref>), this study was restricted to one important subgroup and leaves additional explanations for the comorbidity and course of these two disorders unresolved. We addressed the interrelation of OCS and long-term antipsychotic treatment in stabilized patients. Although our results further support assumed pharmacodynamic mechanisms in the development of second-onset OCS, the observational nature of our study precludes causal attribution (<xref ref-type="bibr" rid="bibr5-0269881112463470">Bradford Hill, 2011</xref>).</p>
<p>We acknowledge further limitations. With the restriction to only two investigation time points during the 12-month observation period we may have missed transient OCS or substantial remission of OCS between assessments. Further research with more frequent assessment time points seems necessary to decipher the detailed longitudinal interaction of SGA treatment and the course of OCS. This study is further limited by the lack of blinded rating and the loss of participants during the course of the study, which caused a significant reduction in sample size. To account for possible confounding effects due to more impaired dropouts within group II, we also evaluated the course of OCS within the total sample with baseline observations carried forward. This approach showed similar results to findings observed in the size-reduced PP sample. In addition, differences in illness duration at baseline may have had an effect on observed between-group difference. However, integrating this factor as a covariate did not significantly change our results.</p>
<p>Future studies should further address pharmacological mechanisms in the development of OCS in early stages of schizophrenia, and investigate possible genetic risk factors, and neural correlates using functional magnetic imaging.</p>
</sec>
</sec>
<sec id="section16-0269881112463470" sec-type="conclusions">
<title>Conclusion</title>
<p>This prospective observational investigation provides results showing persistently high OCS in a subgroup of patients under ongoing antiserotonergic SGA treatment and further hints towards differential effects of SGAs according to their pharmacodynamic profiles. Comorbid OCS are a case for clinical concern (<xref ref-type="bibr" rid="bibr34-0269881112463470">Mukhopadhaya et al., 2009</xref>), they are often undetected, but meaningful for treatment response and general prognosis. From a therapeutic point of view, our results emphasize the need for early detection and monitoring of OCS. Forthcoming treatment trials should focus on possible pharmacological and CBT interventions in schizophrenia patients suffering from comorbid OCS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>FS was supported by a grant of Evangelisches Studienwerk, S. Eifler, FR and CE were not supported from third parties. S. Englisch has received travel expenses and consultant fees from AstraZeneca, Bristol-Myers Squibb GmbH &amp; CoKGaA, Eli-Lilly, Janssen Cilag, Lundbeck, Otsuka Pharma and Pfizer Pharma and Servier. A.M.-L. receives consultant fees and travel expenses from AstraZeneca, Hoffmann-La Roche, Lundbeck Foundation, speaker’s fees from Pfizer Pharma, Lilly Deutschland, Glaxo SmithKline, Janssen Cilag, Bristol-Myers Squibb, Lundbeck and AstraZeneca. MZ received unrestricted scientific grants of the European Research Advisory Board (ERAB), German Research Foundation (DFG), Pfizer Pharma GmbH, Servier and Bristol Myers Squibb Pharmaceuticals; further speaker and travel grants were provided from Astra Zeneca, Lilly, Pfizer Pharma GmbH, Bristol Myers Squibb Pharmaceuticals and Janssen Cilag.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was funded by an unrestricted scientific grant to FS by the Evangelisches Studienwerk. No further third-party-funding.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Achim</surname><given-names>AM</given-names></name>
<name><surname>Maziade</surname><given-names>M</given-names></name>
<name><surname>Raymond</surname><given-names>E</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association</article-title>. <source>Schizophr Bull</source> <volume>37</volume>: <fpage>811</fpage>–<lpage>821</lpage>.</citation>
</ref>
<ref id="bibr2-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Asenjo Lobos</surname><given-names>C</given-names></name>
<name><surname>Komossa</surname><given-names>K</given-names></name>
<name><surname>Rummel-Kluge</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Clozapine versus other atypical antipsychotics for schizophrenia</article-title>. <source>Cochrane Database Syst Rev</source> <volume>11</volume>: <fpage>CD006633</fpage>.</citation>
</ref>
<ref id="bibr3-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baker</surname><given-names>RW</given-names></name>
<name><surname>Chengappa</surname><given-names>KN</given-names></name>
<name><surname>Baird</surname><given-names>JW</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Emergence of obsessive compulsive symptoms during treatment with clozapine</article-title>. <source>J Clin Psychiatry</source> <volume>53</volume>: <fpage>439</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr4-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bloch</surname><given-names>MH</given-names></name>
<name><surname>Landeros-Weisenberger</surname><given-names>A</given-names></name>
<name><surname>Kelmendi</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder</article-title>. <source>Mol Psychiatry</source> <volume>11</volume>: <fpage>622</fpage>–<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr5-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bradford Hill</surname><given-names>A</given-names></name>
</person-group> (<year>2011</year>) <article-title>The environment and disease: association or causation?</article-title> <source>Bull World Health Org</source> <volume>83</volume>: <fpage>295</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr6-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buckley</surname><given-names>PF</given-names></name>
<name><surname>Miller</surname><given-names>BJ</given-names></name>
<name><surname>Lehrer</surname><given-names>DS</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Psychiatric comorbidities and schizophrenia</article-title>. <source>Schizophr Bull</source> <volume>35</volume>: <fpage>383</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr7-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>JS</given-names></name>
<name><surname>Ahn</surname><given-names>Y-M</given-names></name>
<name><surname>Park</surname><given-names>HJ</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial</article-title>. <source>J Clin Psychiatry</source> <volume>69</volume>: <fpage>720</fpage>–<lpage>731</lpage>.</citation>
</ref>
<ref id="bibr8-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Connor</surname><given-names>KM</given-names></name>
<name><surname>Payne</surname><given-names>VM</given-names></name>
<name><surname>Gadde</surname><given-names>KM</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients</article-title>. <source>J Clin Psychiatry</source> <volume>66</volume>: <fpage>49</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr9-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cunill</surname><given-names>R</given-names></name>
<name><surname>Castells</surname><given-names>X</given-names></name>
<name><surname>Simeon</surname><given-names>D</given-names></name>
</person-group> (<year>2009</year>) <article-title>Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis</article-title>. <source>J Clin Psychiatry</source> <volume>70</volume>: <fpage>70</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr10-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Haan</surname><given-names>L</given-names></name>
<name><surname>Beuk</surname><given-names>N</given-names></name>
<name><surname>Hoogenboom</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders</article-title>. <source>J Clin Psychiatry</source> <volume>63</volume>: <fpage>104</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr11-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Haan</surname><given-names>L</given-names></name>
<name><surname>Hoogenboom</surname><given-names>B</given-names></name>
<name><surname>Beuk</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Obsessive–compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders</article-title>. <source>Can J Psychiatry</source> <volume>50</volume>: <fpage>519</fpage>–<lpage>524</lpage>.</citation>
</ref>
<ref id="bibr12-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Haan</surname><given-names>L</given-names></name>
<name><surname>Hoogeboom</surname><given-names>B</given-names></name>
<name><surname>Beuk</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients</article-title>. <source>Psychopharmacol Bull</source> <volume>39</volume>: <fpage>25</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr13-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Haan</surname><given-names>L</given-names></name>
<name><surname>Linszen</surname><given-names>DH</given-names></name>
<name><surname>Gorsira</surname><given-names>R</given-names></name>
</person-group> (<year>1999</year>) <article-title>Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders</article-title>. <source>J Clin Psychiatry</source> <volume>60</volume>: <fpage>364</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr14-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Haan</surname><given-names>L</given-names></name>
<name><surname>Oekeneva</surname><given-names>A</given-names></name>
<name><surname>van</surname><given-names>AT</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders</article-title>. <source>Eur Psychiatry</source> <volume>19</volume>: <fpage>524</fpage>.</citation>
</ref>
<ref id="bibr15-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Haan</surname><given-names>L</given-names></name>
<name><surname>Sterk</surname><given-names>B</given-names></name>
<name><surname>Wouters</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>The 5-year course of obsessive–compulsive symptoms and obsessive–compulsive disorder in first-episode schizophrenia and related disorders</article-title>. <source>Schizophr Bull</source> doi:<pub-id pub-id-type="doi">10.1093/schbul/sbr077</pub-id>.</citation>
</ref>
<ref id="bibr16-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dold</surname><given-names>M</given-names></name>
<name><surname>Aigner</surname><given-names>M</given-names></name>
<name><surname>Lanzenberger</surname><given-names>R</given-names></name><etal/>
</person-group>. S (<year>2011</year>) <article-title>Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive–compulsive disorder – a meta-analysis of double-blind, randomised, placebo-controlled trials</article-title>. <source>Fortschr Neurol Psychiatr</source> <volume>79</volume>: <fpage>453</fpage>–<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr17-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Englisch</surname><given-names>S</given-names></name>
<name><surname>Esslinger</surname><given-names>C</given-names></name>
<name><surname>Inta</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Clozapine-induced obsessive compulsive syndromes improve in combination with aripiprazole</article-title>. <source>Clin Neuropharmacol</source> <volume>32</volume>: <fpage>227</fpage>–<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr18-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erbfelder</surname><given-names>E</given-names></name>
<name><surname>Faul</surname><given-names>F</given-names></name>
<name><surname>Buchner</surname><given-names>A</given-names></name>
</person-group> (<year>1996</year>) <article-title>GPOWER: A general power analysis program</article-title>. <source>Behav Res Methods Instrum Comput</source> <volume>28</volume>: <fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr19-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fenton</surname><given-names>WS</given-names></name>
<name><surname>McGlashan</surname><given-names>TH</given-names></name>
</person-group> (<year>1986</year>) <article-title>The prognostic significance of obsessive-compulsive symptoms in schizophrenia</article-title>. <source>Am J Psychiatry</source> <volume>143</volume>: <fpage>437</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr20-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fontenelle</surname><given-names>LF</given-names></name>
<name><surname>Lin</surname><given-names>A</given-names></name>
<name><surname>Pantelis</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>A longitudinal study of obsessive–compulsive disorder in individuals at ultra-high risk for psychosis</article-title>. <source>J Psychiatr Res</source> <volume>45</volume>: <fpage>1140</fpage>–<lpage>1145</lpage>.</citation>
</ref>
<ref id="bibr21-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gardner</surname><given-names>DM</given-names></name>
<name><surname>Murphy</surname><given-names>AL</given-names></name>
<name><surname>O’Donnell</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>International consensus study of antipsychotic dosing</article-title>. <source>Am J Psychiatry</source> <volume>167</volume>: <fpage>686</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr22-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>MY</given-names></name>
<name><surname>Kim</surname><given-names>SW</given-names></name>
<name><surname>Yum</surname><given-names>SY</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Management of schizophrenia with obsessive-compulsive features</article-title>. <source>Psychiatr Clin North Am</source> <volume>32</volume>: <fpage>835</fpage>–<lpage>851</lpage>.</citation>
</ref>
<ref id="bibr23-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joober</surname><given-names>R</given-names></name>
<name><surname>Boksa</surname><given-names>P</given-names></name>
</person-group> (<year>2010</year>) <article-title>Clozapine: a distinct, poorly understood and under-used molecule</article-title>. <source>J Psychiatry Neurosci</source> <volume>35</volume>: <fpage>147</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr24-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kane</surname><given-names>J</given-names></name>
<name><surname>Honigfeld</surname><given-names>G</given-names></name>
<name><surname>Singer</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>1988</year>) <article-title>Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</article-title>. <source>Arch Gen Psychiatry</source> <volume>45</volume>: <fpage>789</fpage>–<lpage>796</lpage>.</citation>
</ref>
<ref id="bibr25-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kang</surname><given-names>X</given-names></name>
<name><surname>Simpson</surname><given-names>GM</given-names></name>
</person-group> (<year>2010</year>) <article-title>Clozapine: more side effects but still the best antipsychotic</article-title>. <source>J Clin Psychiatry</source> <volume>71</volume>: <fpage>982</fpage>–<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr26-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SW</given-names></name>
<name><surname>Shin</surname><given-names>IS</given-names></name>
<name><surname>Kim</surname><given-names>JM</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study</article-title>. <source>J Clin Psychopharmacol</source> <volume>28</volume>: <fpage>349</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr27-0269881112463470">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Klepsch</surname><given-names>R</given-names></name>
<name><surname>Zaworka</surname><given-names>W</given-names></name>
<name><surname>Hand</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>1993</year>) <source xml:lang="de">Hamburger Zwangsinventar–Kurzform (HZI-K)</source>. Manual [<trans-source>Hamburg Obsessive–Compulsive Inventory – short form (HZI-K)</trans-source>]. <publisher-loc>Goettingen</publisher-loc>: <publisher-name>Beltz TestGmbH</publisher-name>.</citation>
</ref>
<ref id="bibr28-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koran</surname><given-names>LM</given-names></name>
<name><surname>Hanna</surname><given-names>GL</given-names></name>
<name><surname>Hollander</surname><given-names>E</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Practice guideline for the treatment of patients with obsessive–compulsive disorder</article-title>. <source>Am J Psychiatry</source> <volume>164</volume>: <fpage>5</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr29-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kwon</surname><given-names>JS</given-names></name>
<name><surname>Joo</surname><given-names>YH</given-names></name>
<name><surname>Nam</surname><given-names>HJ</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive–compulsive symptoms</article-title>. <source>Arch Gen Psychiatry</source> <volume>66</volume>: <fpage>1233</fpage>–<lpage>1241</lpage>.</citation>
</ref>
<ref id="bibr30-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>SK</given-names></name>
<name><surname>Su</surname><given-names>SF</given-names></name>
<name><surname>Pan</surname><given-names>CH</given-names></name>
</person-group> (<year>2006</year>) <article-title>Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms</article-title>. <source>Ther Drug Monit</source> <volume>28</volume>: <fpage>303</fpage>–<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr31-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lykouras</surname><given-names>L</given-names></name>
<name><surname>Alevizos</surname><given-names>B</given-names></name>
<name><surname>Michalopoulou</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Obsessive–compulsive symptoms induced by atypical antipsychotics. A review of the reported cases</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>27</volume>: <fpage>333</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr32-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lysaker</surname><given-names>PH</given-names></name>
<name><surname>Whitney</surname><given-names>KA</given-names></name>
</person-group> (<year>2009</year>) <article-title>Obsessive–compulsive symptoms in schizophrenia: prevalence, correlates and treatment</article-title>. <source>Expert Rev Neurother</source> <volume>9</volume>: <fpage>99</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr33-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McEvoy</surname><given-names>JP</given-names></name>
<name><surname>Lieberman</surname><given-names>JA</given-names></name>
<name><surname>Stroup</surname><given-names>TS</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</article-title>. <source>Am J Psychiatry</source> <volume>163</volume>: <fpage>600</fpage>–<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr34-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mukhopadhaya</surname><given-names>K</given-names></name>
<name><surname>Krishnaiah</surname><given-names>R</given-names></name>
<name><surname>Taye</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Obsessive–compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern</article-title>. <source>J Psychopharmacol</source> <volume>23</volume>: <fpage>6</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr35-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muscatello</surname><given-names>MR</given-names></name>
<name><surname>Bruno</surname><given-names>A</given-names></name>
<name><surname>Pandolfo</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study</article-title>. <source>J Clin Psychopharmacol</source> <volume>31</volume>: <fpage>174</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr36-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niendam</surname><given-names>TA</given-names></name>
<name><surname>Berzak</surname><given-names>J</given-names></name>
<name><surname>Cannon</surname><given-names>TD</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Obsessive compulsive symptoms in the psychosis prodrome: correlates of clinical and functional outcome</article-title>. <source>Schizophr Res</source> <volume>108</volume>: <fpage>170</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr37-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohoyama</surname><given-names>K</given-names></name>
<name><surname>Yamamura</surname><given-names>S</given-names></name>
<name><surname>Hamaguchi</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex</article-title>. <source>Eur J Pharmacol</source> <volume>653</volume>: <fpage>47</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr38-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poyurovsky</surname><given-names>M</given-names></name>
<name><surname>Weizman</surname><given-names>A</given-names></name>
<name><surname>Weizman</surname><given-names>R</given-names></name>
</person-group> (<year>2004</year>) <article-title>Obsessive–compulsive disorder in schizophrenia: clinical characteristics and treatment</article-title>. <source>CNS Drugs</source> <volume>18</volume>: <fpage>989</fpage>–<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr39-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poyurovsky</surname><given-names>M</given-names></name>
<name><surname>Zohar</surname><given-names>J</given-names></name>
<name><surname>Glick</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Obsessive–compulsive symptoms in schizophrenia: implications for future psychiatric classifications</article-title>. <source>Compr Psychiatry</source> <volume>53</volume>: <fpage>480</fpage>–<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr40-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reznik</surname><given-names>I</given-names></name>
<name><surname>Yavin</surname><given-names>I</given-names></name>
<name><surname>Stryjer</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Clozapine in the treatment of obsessive–compulsive symptoms in schizophrenia patients: a case series study</article-title>. <source>Pharmacopsychiatry</source> <volume>37</volume>: <fpage>52</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr41-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rocha</surname><given-names>FL</given-names></name>
<name><surname>Hara</surname><given-names>C</given-names></name>
</person-group> (<year>2006</year>) <article-title>Benefits of combining aripiprazole to clozapine: Three case reports</article-title>. <source>Progr Neuropsychopharmacol Biol Psychiatry</source> <volume>30</volume>: <fpage>1167</fpage>–<lpage>1169</lpage>.</citation>
</ref>
<ref id="bibr42-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosa-Alcazar</surname><given-names>AI</given-names></name>
<name><surname>Sanchez-Meca</surname><given-names>J</given-names></name>
<name><surname>Gomez-Conesa</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Psychological treatment of obsessive-compulsive disorder: A meta-analysis</article-title>. <source>Clin Psychol Rev</source> <volume>28</volume>: <fpage>1310</fpage>–<lpage>1325</lpage>.</citation>
</ref>
<ref id="bibr43-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ryu</surname><given-names>S</given-names></name>
<name><surname>Oh</surname><given-names>S</given-names></name>
<name><surname>Cho</surname><given-names>EY</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive–compulsive symptoms</article-title>. <source>Am J Med Genet</source> <volume>156</volume>: <fpage>949</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr44-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scatton</surname><given-names>B</given-names></name>
<name><surname>Claustre</surname><given-names>Y</given-names></name>
<name><surname>Cudennec</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Amisulpride: from animal pharmacology to therapeutic action</article-title>. <source>Int Clin Psychopharmacol</source> <volume>12</volume>(<supplement>Suppl 2</supplement>): <fpage>S29</fpage>–<lpage>S36</lpage>.</citation>
</ref>
<ref id="bibr45-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schirmbeck</surname><given-names>F</given-names></name>
<name><surname>Esslinger</surname><given-names>C</given-names></name>
<name><surname>Rausch</surname><given-names>F</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia</article-title>. <source>Psychol Med</source> <volume>41</volume>: <fpage>2361</fpage>–<lpage>2374</lpage>.</citation>
</ref>
<ref id="bibr46-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schirmbeck</surname><given-names>F</given-names></name>
<name><surname>Nieratschker</surname><given-names>V</given-names></name>
<name><surname>Frank</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive compulsive symptoms induced by second generation antipsychotic agents</article-title>. <source>Psychiatr Genet</source> <volume>22</volume>: <fpage>245</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr47-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schirmbeck</surname><given-names>F</given-names></name>
<name><surname>Zink</surname><given-names>M</given-names></name>
</person-group> (<year>2012</year>) <article-title>Clozapine-induced obsessive–compulsive symptoms in schizophrenia: A critical review</article-title>. <source>Curr Neuropharmacol</source> <volume>10</volume>: <fpage>88</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr48-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sevincok</surname><given-names>L</given-names></name>
<name><surname>Akoglu</surname><given-names>A</given-names></name>
<name><surname>Kokcu</surname><given-names>F</given-names></name>
</person-group> (<year>2007</year>) <article-title>Suicidality in schizophrenic patients with and without obsessive–compulsive disorder</article-title>. <source>Schizophr Res</source> <volume>90</volume>: <fpage>198</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr49-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sparshatt</surname><given-names>A</given-names></name>
<name><surname>Taylor</surname><given-names>D</given-names></name>
<name><surname>Patel</surname><given-names>MX</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring</article-title>. <source>J Clin Psychiatry</source> <volume>71</volume>: <fpage>1447</fpage>–<lpage>1456</lpage>.</citation>
</ref>
<ref id="bibr50-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tiihonen</surname><given-names>J</given-names></name>
<name><surname>Lonnqvist</surname><given-names>J</given-names></name>
<name><surname>Wahlbeck</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)</article-title>.[see comment]. <source>Lancet</source> <volume>374</volume>: <fpage>620</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr51-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villari</surname><given-names>V</given-names></name>
<name><surname>Frieri</surname><given-names>T</given-names></name>
<name><surname>Fagiolini</surname><given-names>A</given-names></name>
</person-group> (<year>2011</year>) <article-title>Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms</article-title>. <source>J Clin Psychopharmacol</source> <volume>31</volume>: <fpage>375</fpage>–<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr52-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westphal</surname><given-names>K</given-names></name>
</person-group> (<year>1878</year>) <article-title>Ueber Zwangsvorstellungen</article-title>. <source>Arch Psychiatr Nervenkr</source> <volume>8</volume>: <fpage>734</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr53-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woody</surname><given-names>SR</given-names></name>
<name><surname>Steketee</surname><given-names>G</given-names></name>
<name><surname>Chambless</surname><given-names>DL</given-names></name>
</person-group> (<year>1995</year>) <article-title>Reliability and validity of the Yale-Brown Obsessive–Compulsive Scale</article-title>. <source>Behav Res Ther</source> <volume>33</volume>: <fpage>597</fpage>–<lpage>605</lpage>.</citation>
</ref>
<ref id="bibr54-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>KC</given-names></name>
<name><surname>Su</surname><given-names>TP</given-names></name>
<name><surname>Chou</surname><given-names>YH</given-names></name>
</person-group> (<year>2008</year>) <article-title>Effectiveness of aripiprazole in treating obsessive compulsive symptoms</article-title>. <source>Progr Neuropsychopharmacol Biol Psychiatry</source> <volume>32</volume>: <fpage>585</fpage>–<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr55-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zink</surname><given-names>M</given-names></name>
<name><surname>Englisch</surname><given-names>S</given-names></name>
<name><surname>Knopf</surname><given-names>U</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Augmentation of clozapine with valproic acid for clozapine-induced obsessive compulsive symptoms</article-title>. <source>Pharmacopsychiatry</source> <volume>40</volume>: <fpage>202</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr56-0269881112463470">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zink</surname><given-names>M</given-names></name>
<name><surname>Knopf</surname><given-names>U</given-names></name>
<name><surname>Kuwilsky</surname><given-names>A</given-names></name>
</person-group> (<year>2006</year>) <article-title>Management of clozapine-induced obsessive compulsive symptoms in a man with schizophrenia</article-title>. <source>Austr NZ J Psychiatry</source> <volume>41</volume>: <fpage>293</fpage>–<lpage>294</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>